Cargando…

Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy

BACKGROUND: Previous studies have shown that microRNA-32 (miRNA-32) is an exosome microRNA that affects the proliferation and metastasis of non-small cell lung cancer (NSCLC) cells. In this study, our goal was to assess the expression of plasma microRNA-32 and its potential as a biomarker to predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Shuyuan, Li, Jing, Chen, Ling, Guo, Li, Ye, Mei, Wu, Yuanyuan, Ji, Quanjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824696/
https://www.ncbi.nlm.nih.gov/pubmed/31626089
http://dx.doi.org/10.1097/MD.0000000000017335
_version_ 1783464780247334912
author Xu, Shuyuan
Li, Jing
Chen, Ling
Guo, Li
Ye, Mei
Wu, Yuanyuan
Ji, Quanjiang
author_facet Xu, Shuyuan
Li, Jing
Chen, Ling
Guo, Li
Ye, Mei
Wu, Yuanyuan
Ji, Quanjiang
author_sort Xu, Shuyuan
collection PubMed
description BACKGROUND: Previous studies have shown that microRNA-32 (miRNA-32) is an exosome microRNA that affects the proliferation and metastasis of non-small cell lung cancer (NSCLC) cells. In this study, our goal was to assess the expression of plasma microRNA-32 and its potential as a biomarker to predict the tumor response and survival of patients with NSCLC undergoing platinum-based chemotherapy. METHODS: Plasma microRNA-32 levels before and after 1 cycle of platinum-based chemotherapy in 43 patients with NSCLC were measured using a quantitative real-time polymerase chain reaction assay (qPCR). In addition, the demographic and survival data of the patients were collected for analysis. RESULTS: A significant correlation was observed between the changes in microRNA-32 levels before and after 1 chemotherapy cycle and the treatment response (P = .035). In addition, Kaplan–Meier analysis showed that the level of microRNA-32 after 1 chemotherapy cycle was significantly correlated with the prognosis of patients. The median progression-free survival (P = .025) and overall survival (P = .015) of patients with high microRNA-32 levels (≥7.73) after 1 chemotherapy cycle was 9 and 21 months, respectively. In contrast, the median survival of patients with low microRNA-32 levels (<7.73) was 5 and 10 months, respectively. CONCLUSIONS: The plasma levels of microRNA-32 correlated with the efficacy of platinum-based chemotherapy and survival, indicating that microRNA-32 may be useful for predicting the effectiveness of platinum-based chemotherapy and prognosis in NSCLC.
format Online
Article
Text
id pubmed-6824696
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-68246962019-11-19 Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy Xu, Shuyuan Li, Jing Chen, Ling Guo, Li Ye, Mei Wu, Yuanyuan Ji, Quanjiang Medicine (Baltimore) 5700 BACKGROUND: Previous studies have shown that microRNA-32 (miRNA-32) is an exosome microRNA that affects the proliferation and metastasis of non-small cell lung cancer (NSCLC) cells. In this study, our goal was to assess the expression of plasma microRNA-32 and its potential as a biomarker to predict the tumor response and survival of patients with NSCLC undergoing platinum-based chemotherapy. METHODS: Plasma microRNA-32 levels before and after 1 cycle of platinum-based chemotherapy in 43 patients with NSCLC were measured using a quantitative real-time polymerase chain reaction assay (qPCR). In addition, the demographic and survival data of the patients were collected for analysis. RESULTS: A significant correlation was observed between the changes in microRNA-32 levels before and after 1 chemotherapy cycle and the treatment response (P = .035). In addition, Kaplan–Meier analysis showed that the level of microRNA-32 after 1 chemotherapy cycle was significantly correlated with the prognosis of patients. The median progression-free survival (P = .025) and overall survival (P = .015) of patients with high microRNA-32 levels (≥7.73) after 1 chemotherapy cycle was 9 and 21 months, respectively. In contrast, the median survival of patients with low microRNA-32 levels (<7.73) was 5 and 10 months, respectively. CONCLUSIONS: The plasma levels of microRNA-32 correlated with the efficacy of platinum-based chemotherapy and survival, indicating that microRNA-32 may be useful for predicting the effectiveness of platinum-based chemotherapy and prognosis in NSCLC. Wolters Kluwer Health 2019-10-18 /pmc/articles/PMC6824696/ /pubmed/31626089 http://dx.doi.org/10.1097/MD.0000000000017335 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 5700
Xu, Shuyuan
Li, Jing
Chen, Ling
Guo, Li
Ye, Mei
Wu, Yuanyuan
Ji, Quanjiang
Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy
title Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy
title_full Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy
title_fullStr Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy
title_full_unstemmed Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy
title_short Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy
title_sort plasma mir-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824696/
https://www.ncbi.nlm.nih.gov/pubmed/31626089
http://dx.doi.org/10.1097/MD.0000000000017335
work_keys_str_mv AT xushuyuan plasmamir32levelsinnonsmallcelllungcancerpatientsreceivingplatinumbasedchemotherapycanpredicttheeffectivenessandprognosisofchemotherapy
AT lijing plasmamir32levelsinnonsmallcelllungcancerpatientsreceivingplatinumbasedchemotherapycanpredicttheeffectivenessandprognosisofchemotherapy
AT chenling plasmamir32levelsinnonsmallcelllungcancerpatientsreceivingplatinumbasedchemotherapycanpredicttheeffectivenessandprognosisofchemotherapy
AT guoli plasmamir32levelsinnonsmallcelllungcancerpatientsreceivingplatinumbasedchemotherapycanpredicttheeffectivenessandprognosisofchemotherapy
AT yemei plasmamir32levelsinnonsmallcelllungcancerpatientsreceivingplatinumbasedchemotherapycanpredicttheeffectivenessandprognosisofchemotherapy
AT wuyuanyuan plasmamir32levelsinnonsmallcelllungcancerpatientsreceivingplatinumbasedchemotherapycanpredicttheeffectivenessandprognosisofchemotherapy
AT jiquanjiang plasmamir32levelsinnonsmallcelllungcancerpatientsreceivingplatinumbasedchemotherapycanpredicttheeffectivenessandprognosisofchemotherapy